Sermorelin research: what GHRH(1-29) measured in growth, aging, and cognition

Start here

Sermorelin research has two firm anchors and a wide, softer frontier. The firm anchors: in growth-deficient children it sped up growth, and in older men it pushed an aged growth-hormone system back toward a younger range. The softer frontier is everything marketed to adults — fat loss, muscle, anti-aging — where the direct sermorelin evidence thins out and the best body-composition numbers actually come from a close relative, tesamorelin. This page leads with what is established, names the related-analog data as related-analog data, and leaves the empty spaces empty. IGF-1, mentioned throughout, is the liver-made growth signal that rises when growth hormone rises.

What the research reports on sermorelin's effects

The sermorelin benefits discussed in the literature are best read as measured outcomes, not promises.

Pediatric growth (the approved use). In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth, raising first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year — without excessive IGF-1 generation ^[2]. This is the clearest efficacy signal in the entire record, and it is the use sermorelin was approved for.

Reversing the aging GH/IGF-1 decline. In healthy old men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose ^[3]. The aged axis responded to the upstream signal.

Cognition and IGF-1 (a related analog). In a randomized, double-blind, placebo-controlled trial of 152 older adults — 66 with mild cognitive impairment — 20 weeks of a daily GHRH analog (tesamorelin, given before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% ^[7]. Promising, but a single trial of a related analog — not a treatment claim for sermorelin itself.

Reported side effects and safety considerations of sermorelin

Reported adverse effects in the sermorelin side effects literature were generally mild, with injection-site reactions the most common; in the GHRH-analog cognition trial, adverse events were described as mild ^[7]. The aging study in older men reported no effect on fasting glucose at the doses used ^[3].

The principal theoretical concern is class-wide rather than sermorelin-specific. Growth hormone and IGF-1 are mitogenic — they drive cell growth — so chronically raising them is theorized to carry an oncologic consideration, even though sermorelin acts through the body's own feedback-regulated, pulsatile secretion rather than flooding the system. Long-term safety data specifically for adult, non-deficiency use remain limited ^[7]. Growth-hormone secretagogues, including GHRH analogs, are also prohibited in sport by WADA, and dedicated detection methods exist. None of this is medical advice; it is the safety frame the published record carries.

Comparisons: sermorelin against its neighbors

Sermorelin vs tesamorelin

Sermorelin is native GHRH(1-29); tesamorelin is a stabilized GHRH analog with a longer duration and the body-composition track record sermorelin lacks. The clearest controlled body-composition and cognition data in this corpus come from tesamorelin — the 117% IGF-1 rise and 7.4% body-fat reduction in the cognition trial were tesamorelin results ^[7]. When this digest reports fat-loss numbers, they belong to tesamorelin unless explicitly stated otherwise; that line is held deliberately, because adult body-composition marketing tends to attach tesamorelin's data to sermorelin's name.

Sermorelin vs ipamorelin: what is the difference?

Sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor — a different mechanism entirely ^[4]. In adult female rats, the GHRPs ipamorelin and GHRP-6 increased bone mineral content, an effect attributed to that distinct secretagogue class ^[4]. The two reach more growth hormone by separate routes, and their non-GH effects do not transfer between classes.

Efficacy, timeline, and the honest frontier

Does sermorelin work?

In its approved pediatric indication, once-daily subcutaneous GHRH(1-29) accelerated growth in deficient children (height velocity ~4.1 to ~7-8 cm/year) ^[2], and in older men 14 days of dosing reversed age-related GH and IGF-1 declines ^[3]. Adult anti-aging efficacy is far less established — an editorial called secretagogue anti-aging use "not yet ready for prime time" ^[14].

How long does it take for sermorelin to work?

Acute growth-hormone release follows a single dose within hours — GH stayed elevated for about 3 hours after an intravenous dose ^[13] — while the aging study measured GH/IGF-1 changes over 14 days ^[3] and the pediatric growth endpoint was assessed over the first year ^[2]. These are study endpoints, not personal expectations.

Does sermorelin burn fat? Is it effective for weight loss?

No sermorelin study establishes it as a fat-loss or weight-loss treatment. The closest controlled body-composition data come from the related analog tesamorelin and from the GHRH cognition trial that reported a 7.4% reduction in percent body fat ^[7]. Anti-aging and body-composition marketing outpaces the direct sermorelin evidence, and a comprehensive 2025 review of GHRH and its analogues frames the therapeutic landscape with the same caution ^[15].

Will sermorelin raise my IGF-1 levels?

In healthy older men, GHRH(1-29) twice daily for 14 days produced dose-related increases in GH and IGF-1, with high-dose values no longer differing from young men ^[3]; a related GHRH analog raised IGF-1 by 117% within the physiologic range ^[7]. Reported as study outcomes, not a personal prediction.

Does sermorelin build muscle?

The corpus contains no controlled sermorelin muscle-hypertrophy trial. GH/IGF-1-axis modulation has been discussed in reviews as a candidate strategy against age-related muscle loss, but that is framing, not proof ^[15].

Sermorelin before and after: what changes do studies report?

Measured before/after changes in the literature include accelerated height velocity in deficient children (~4.1 to ~7-8 cm/year) ^[2], reversal of age-related GH/IGF-1 declines in older men ^[3], and — for the related GHRH analog — a 117% IGF-1 increase with a 7.4% body-fat reduction ^[7]. These are trial outcomes, not personal results.

What is sermorelin used for?

Historically it was an FDA-approved prescription product (NDA 020443) used to evaluate and treat growth-hormone deficiency and short stature in children, and it was also used diagnostically as a GHRH stimulation agent. Adult GH-axis research has examined aging, body composition, sleep, and cognition; those non-pediatric uses are research contexts, not approved indications.

Does sermorelin affect the brain?

GHRH administration has measurable neuroendocrine effects: a GHRH analog had a favorable effect on cognition in older adults ^[7], and GHRH influences slow-wave sleep, the stage tied to nocturnal GH. These are research observations in study populations.

Can sermorelin or GHRH improve cognition in older adults?

In a randomized, double-blind, placebo-controlled trial of 152 older adults (including 66 with mild cognitive impairment), 20 weeks of a daily GHRH analog had a favorable effect on cognition (P=0.03; executive function P=0.005), alongside a 117% IGF-1 rise and a 7.4% body-fat reduction ^[7]. Promising, but a single trial of a related analog — not a treatment claim for sermorelin.